Samsung Biologics · 임원ㆍ주요주주특정증권등소유상황보고서
Report on Specified Securities Owned by Officers and Major Shareholders
6.1
삼성바이오로직스
20261118
Report on Specified Securities Owned by Officers and Major Shareholders
| To: Securities and Futures Commission | ||
| To: Korea Exchange | ||
| Reporting obligation date: | 2026-11-18 | |
| Report reference date: | 2026-11-18 | |
| ※ The reporting person confirms that ownership of specified securities as of the reference date is accurately stated per applicable laws and filing instructions, with no material misstatement or omission. |
| Reporting person: | Samsung C&T Corporation |
| Company Name | Samsung Biologics Co., Ltd. | ||
| Entity type | KOSPI-listed company | Company code | 207940 |
| Total Shares Issued | 48,560,951 | ||
| Report Type | Change | Reporting person type | Domestic corporation | |
| Name (Entity Name) | Korean | Samsung C&T Corporation | Chinese characters (English) | 三星物産(株)(Samsung C&TCorporation) |
| Date of Birth or Business Registration No., etc. | 202-81-45975 | |||
| Address (Head Office) [Town/District Level Only] | 서울특별시 강동구 상일로 | |||
| Relationship to Issuer | Officer (Registered or Not) | - | Position | - |
| Appointment Date | - | Resignation Date | - | |
| Major Shareholder | 10%+ shareholder | |||
| Business contact and person in charge | Affiliated company | Samsung C&T Corporation | Department | IR금융팀 |
| Position | 프로 | Phone Number | 02-214** | |
| Name | 신동아 | Fax number | 02-202** | |
| Email address | **[email protected] | |||
| Report reference date | Specified Securities | Share Certificates | |||
| Number of Specified Securities (shares) | Ratio (%) | Number of Shares (shares) | Ratio (%) | ||
| Previous Report | 2026-10-19 | 20,715,168 | 44.01 | 19,932,350 | 43.06 |
| This Report | 2026-11-18 | 20,715,168 | 42.66 | 20,715,168 | 42.66 |
| Change | 0 | -1.35 | 782,818 | -0.4 | |
| Details of Specified Securities | |||||||||
| Share certificates | Instruments representing preemptive rights | Convertible bonds | Bonds with warrants | Participating Bonds | Exchangeable bonds | Depositary receipts | Other | Total | |
| Number of shares | Ratio (%) | ||||||||
| 20,715,168 | - | - | - | - | - | - | - | 20,715,168 | 42.66 |
| A | B | C | D | E | F | G | H | ||
| I | |||||||||
| Total Shares Issued (J) | Number of Specified Securities Other Than Shares (B+C+D+E+F+G+H=I) | Ownership ratio (%) | |
| Ownership Ratio of Specified Securities [A+I / J+I-(F+G+H)※] × 100 | Shareholding Ratio (A / J) × 100 | ||
| 48,560,951 | - | 42.66 | 42.66 |
※ Ownership ratio excludes from the denominator only exchangeable bonds exchangeable into shares and depositary receipts, derivative-linked securities, etc. with shares as underlying
| Reason for Report | Change Date* | Type of Specified Securities | Shares Owned (shares) | Acquisition/Disposal Unit Price (KRW)** | Remarks | Trading plan report date | ||
| Before Change | Change | After Change | ||||||
| 기타(-) | 2026-11-18 | Instruments representing preemptive rights | 782,818 | -782,818 | 0 | - | 유상신주취득에 따른신주인수권증서 효력 소멸 | - |
| 유상신주취득(+) | 2026-11-18 | Common Stock | 19,932,350 | 782,818 | 20,715,168 | 1,174,000 | 구주주 청약에 따른유상신주취득 | - |
| Total | 20,715,168 | 0 | 20,715,168 | - | - | |||
※ 상기 세부변동내역 중 "취득/처분단가(원)"는 발행회사의 유상증자 신주 발행가액(1,174,000원)임* 증권시장에서 주식등을 매매한 경우에는 그 계약결제일
** For securities other than shares, the exercise (conversion/exchange) price of the securities or the unit price of shares acquired/disposed of through exercise of rights; amounts in ( ) are the unit price of the securities